Novozymes A/S (OTCMKTS:NVZMY) Short Interest Down 60.1% in May

Novozymes A/S (OTCMKTS:NVZMY) saw a large decrease in short interest in May. As of May 29th, there was short interest totaling 12,291 shares, a decrease of 60.1% from the May 14th total of 30,830 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 83,894 shares, the days-to-cover ratio is currently 0.1 days.

Novozymes A/S Stock Down 0.5%

Shares of Novozymes A/S stock traded down $0.31 during trading on Friday, hitting $59.68. 5,719 shares of the stock were exchanged, compared to its average volume of 85,924. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03. The firm’s 50-day moving average price is $59.39 and its 200 day moving average price is $60.41. The stock has a market cap of $24.74 billion, a price-to-earnings ratio of 40.32, a price-to-earnings-growth ratio of 1.13 and a beta of 0.95. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $75.99.

Novozymes A/S (OTCMKTS:NVZMY) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.52%. As a group, analysts forecast that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NVZMY shares. Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, Rothschild & Co Redburn raised shares of Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy”.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).